Our findings indicated that ME1 was highly expressed in several cancers, including bladder cancer (BLCA), breast cancer (BRCA), glioblastoma (GBM), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), pheochromocytoma and paraganglioma (PCPG), prostate cancer (PRAD), stomach cancer (STAD), thyroid cancer (THCA), thymoma (THYM), and uterine corpus endometrial carcinoma (UCEC). Here, ME1 is linked to prostate cancer.